Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-Cancer J Clin. 2021;71(3):209–49.
Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–54.
Article CAS PubMed Google Scholar
Majeed U, Manochakian R, Zhao YJ, Lou YY. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. J Hematol Oncol. 2021;14(1):108.
Article PubMed PubMed Central Google Scholar
Yu W, Zhang X, Zhang W, Xiong MG, Lin YH, Chang M, Xu L, Lu Y, Liu Y, Zhang J. 19-Hydroxybufalin inhibits non-small cell lung cancer cell proliferation and promotes cell apoptosis via the Wnt/β-catenin pathway. Exp Hematol Oncol. 2021;10(1):48.
Article CAS PubMed PubMed Central Google Scholar
Tsimberidou AM, Shaw JV, Juric D, Verschraegen C, Weise AM, Sarantopoulos J, Lopes G, Nemunaitis J, Mita M, Park H, et al. Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer. J Hematol Oncol. 2021;14(1):127.
Article CAS PubMed PubMed Central Google Scholar
Cruz C, Afonso M, Oliveiros B, Pego A. Recurrence and risk factors for relapse in patients with non-small cell lung cancer treated by surgery with curative intent. Oncol-Basel. 2017;92(6):347–52.
Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, Glockner S, Piantadosi S, Gabrielson E, Pridham G, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med. 2008;358(11):1118–28.
Article CAS PubMed Google Scholar
Carnio S, Novello S, Papotti M, Loiacono M, Scagliotti GV. Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures. Transl Lung Cancer Res. 2013;2(5):372–81.
CAS PubMed PubMed Central Google Scholar
Melton KR, Nesslein LL, Ikegami M, Tichelaar JW, Clark JC, Whitsett JA, Weaver TE. SP-B deficiency causes respiratory failure in adult mice. Am J Physiol Lung Cell Mol Physiol. 2003;285(3):L543–9.
Article CAS PubMed Google Scholar
Sin DD, Tammemagi CM, Lam S, Barnett MJ, Duan XB, Tam A, Auman H, Feng ZD, Goodman GE, Hanash S, et al. Pro-surfactant protein B as a biomarker for lung cancer prediction. J Clin Oncol. 2013;31(36):4536–43.
Article PubMed PubMed Central Google Scholar
Xi LQ, Coello MC, Litle VR, Raja S, Gooding WE, Yousem SA, El-Hefnawy T, Landreneau RJ, Luketich JD, Godfrey TE. A combination of molecular markers accurately detects lymph node metastasis in non-small cell lung cancer patients. Clin Cancer Res. 2006;12(8):2484–91.
Article CAS PubMed PubMed Central Google Scholar
Zhang L, Li MX, Deng B, Dai N, Feng Y, Shan JL, Yang YX, Mao CY, Huang P, Xu CX, et al. HLA-DQB1 expression on tumor cells is a novel favorable prognostic factor for relapse in early-stage lung adenocarcinoma. Cancer Manag Res. 2019;11:2605–16.
Article CAS PubMed PubMed Central Google Scholar
Pocha K, Mock A, Rapp C, Dettling S, Warta R, Geisenberger C, Jungk C, Martins LR, Grabe N, Reuss D, et al. Surfactant expression defines an inflamed subtype of lung adenocarcinoma brain metastases that correlates with prolonged survival. Clin Cancer Res. 2020;26(9):2231–43.
Article CAS PubMed Google Scholar
Taguchi A, Hanash S, Rundle A, McKeague IW, Tang DL, Darakjy S, Gaziano JM, Sesso HD, Perera F. Circulating Pro-surfactant protein B as a risk biomarker for lung cancer. Cancer Epidem Biomar. 2013;22(10):1756–61.
Li Q, Zhou ZW, Duan W, Qian CY, Wang SN, Deng MS, Zi D, Wang JM, Mao CY, Song GB, et al. Inhibiting the redox function of APE1 suppresses cervical cancer metastasis via disengagement of ZEB1 from E-cadherin in EMT. J Exp Clin Canc Res. 2021;40(1):220.
Dai FQ, Li CR, Fan XQ, Tan L, Wang RT, Jin H. miR-150-5p Inhibits non-small-cell lung cancer metastasis and recurrence by targeting HMGA2 and beta-catenin signaling. Mol Ther-Nucl Acids. 2019;16:675–85.
Yu T, Zhao Y, Hu Z, Li J, Chu D, Zhang J, Li Z, Chen B, Zhang X, Pan H, et al. MetaLnc9 facilitates lung cancer metastasis via a PGK1-activated AKT/mTOR pathway. Cancer Res. 2017;77(21):5782–94.
Article CAS PubMed Google Scholar
Miallot R, Galland F, Millet V, Blay JY, Naquet P. Metabolic landscapes in sarcomas. J Hematol Oncol. 2021;14(1):114.
Article PubMed PubMed Central Google Scholar
Schreiner P, Chen X, Husnjak K, Randles L, Zhang NX, Elsasser S, Finley D, Dikic I, Walters KJ, Groll M. Ubiquitin docking at the proteasome through a novel pleckstrin-homology domain interaction. Nature. 2008;453(7194):548–52.
Article CAS PubMed PubMed Central Google Scholar
Chen X, Lee BH, Finley D, Walters KJ. Structure of proteasome ubiquitin receptor hRpn13 and its activation by the scaffolding protein hRpn2. Mol Cell. 2010;38(3):404–15.
Article CAS PubMed PubMed Central Google Scholar
Lee S, Kim D, Kang J, Kim E, Kim W, Youn H, Youn B. Surfactant protein B suppresses lung cancer progression by inhibiting secretory phospholipase A2 activity and arachidonic acid production. Cell Physiol Biochem. 2017;42(4):1684–700.
Article CAS PubMed Google Scholar
Tan AC. Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC). Thorac Cancer. 2020;11(3):511–8.
Article PubMed PubMed Central Google Scholar
Hua H, Zhang HY, Chen JZ, Wang J, Liu JY, Jiang YF. Targeting Akt in cancer for precision therapy. J Hematol Oncol. 2021;14(1):128.
Article CAS PubMed PubMed Central Google Scholar
Samart P, Rojanasakul Y, Issaragrisil S, Luanpitpong S. A novel E-cadherin/SOX9 axis regulates cancer stem cells in multiple myeloma by activating Akt and MAPK pathways. Exp Hematol Oncol. 2022;11(1):41.
Article CAS PubMed PubMed Central Google Scholar
Luo XY, Cao MD, Gao F, He XX. YTHDF1 promotes hepatocellular carcinoma progression via activating PI3K/AKT/mTOR signaling pathway and inducing epithelial-mesenchymal transition. Exp Hematol Oncol. 2021;10(1):35.
Article CAS PubMed PubMed Central Google Scholar
Okabe S, Tanaka Y, Gotoh A. Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma. Exp Hematol Oncol. 2021;10(1):19.
Article CAS PubMed PubMed Central Google Scholar
Hsu CY, Lin CH, Jan YH, Su CY, Yao YC, Cheng HC, Hsu TI, Wang PS, Su WP, Yang CJ, et al. Huntingtin-Interacting Protein-1 Is an Early-Stage prognostic biomarker of lung adenocarcinoma and suppresses metastasis via Akt-mediated epithelial-mesenchymal transition. Am J Resp Crit Care. 2016;193(8):869–80.
Li J, Cheng D, Zhu M, Yu H, Pan Z, Liu L, Geng Q, Pan H, Yan M, Yao M. OTUB2 stabilizes U2AF2 to promote the Warburg effect and tumorigenesis via the AKT/mTOR signaling pathway in non-small cell lung cancer. Theranostics. 2019;9(1):179–95.
Article CAS PubMed PubMed Central Google Scholar
He Y, Wang X, Lu W, Zhang D, Huang L, Luo Y, Xiong L, Li H, Zhang P, Li Q, et al. PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4/ERK signaling pathway and accelerating glycolysis. Cell Death Dis. 2022;13(2):118.
Article CAS PubMed PubMed Central Google Scholar
Jiao LY, Ouyang SY, Shaw N, Song GJ, Feng YG, Niu FF, Qiu WC, Zhu HT, Hung LW, Zuo XB, et al. Mechanism of the Rpn13-induced activation of Uch37. Protein Cell. 2014;5(8):616–30.
Article CAS PubMed PubMed Central Google Scholar
Dickson P, Simanski S, Ngundu JM, Kodadek T. Mechanistic studies of the multiple myeloma and melanoma cell-selective toxicity of the Rpn13-binding peptoid KDT-11. Cell Chem Biol. 2020;27(11):1383–95.
Article CAS PubMed PubMed Central Google Scholar
Ma J, Ma S, Zhang Y, Shen Y, Huang L, Lu T, Wang L, Wen Y, Ding Z. Kinectin1 depletion promotes EGFR degradation via the ubiquitin-proteosome system in cutaneous squamous cell carcinoma. Cell Death Dis. 2021;12(11):995.
Comments (0)